A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The primary goal of this Phase 1 study is to characterize the safety and tolerability of
DZ-002 and establish the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)
of DZ-002 administered on a weekly schedule in patients with solid tumors. Pharmacokinetics,
pharmacodynamics, and the anti-tumor activity of DZ-002 will also be assessed.